The Department of Molecular Medicine at Aarhus University Hospital is heading a Danish research project on molecular prediction of prostate cancer risk and aggressiveness, where CLC bio will develop the underlying bioinformatics platform for integrated analysis of microarray data and next generation sequencing data. The $4M project is funded by the Danish Council for Strategic Research.
Professor at the Department of Molecular Medicine at Aarhus University Hospital, Dr Torben Ørntoft, states, 'Prostate cancer is a fast growing health and economical problem in Denmark with an increase of 7.9 per cent of new cases per year for the past 10 years. However, we need to develop much more effective methods of identifying whether it's an aggressive or a non-aggressive form of prostate cancer, so we can provide the right treatments fast and accurately, and thereby increase the number of patients cured, while decreasing the overall spending by preventing overtreatment.'
The goal of the project is to identify and validate new molecular markers for prostate cancer aggressiveness using the bioinformatics tools developed by CLC bio for this project, new NGS technologies, microarray analyses, and one of the world's largest biobanks for prostate cancer tissue with clinical annotation.
